Literature DB >> 7586307

Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts.

R H Schwinger1, M Böhm, U Schmidt, P Karczewski, U Bavendiek, M Flesch, E G Krause, E Erdmann.   

Abstract

BACKGROUND: The aim of the present study was to investigate whether Ca2+ uptake into the sarcoplasmic reticulum (SR) is altered in failing human myocardium resulting from dilated cardiomyopathy. METHODS AND
RESULTS: Ca(2+)-ATPase (SERCA II) activity and Ca(2+)-dependent 45Ca2+ uptake (oxalate supported, steady state) in isolated vesicles from the SR (VSR) and in crude membrane preparations (CSR) (free Ca2+, 0.01 to 100 mumol/L) from nonfailing (donor hearts, n = 13) and terminally failing (heart transplants, dilated cardiomyopathy, n = 17) human myocardium were studied. In the same hearts, protein levels (Western blot analysis) and mRNA levels (Northern blot analysis) of SERCA II and phospholamban were measured. Increasing concentrations of Ca2+ were followed by an increased Ca(2+)-ATPase activity and Ca2+ uptake. Ca2+ uptake activity and Ca(2+)-ATPase activity in CSR preparations from failing myocardium were significantly reduced compared with nonfailing hearts (Ca(2+)-ATPase, 163 +/- 8 and 125 +/- 7 nmol ATP/mg protein per minute for nonfailing tissue and failing tissue in New York Heart Association [NYHA] class IV, respectively; Ca2+ uptake, 7.1 +/- 0.8 and 3.5 +/- 0.3 nmol/mg protein per minute in CSR from nonfailing and NYHA class IV hearts, respectively P < .05). In contrast, no significant difference was measured in VSR. In the same preparations (CSR and VSR), both SERCA II and phospholamban levels (Western blot technique with monoclonal antibodies) were unchanged in failing compared with nonfailing tissue. mRNA expression relative to GAPDH mRNA for SERCA IIa and for phospholamban was significantly reduced in failing human myocardium (P < .05).
CONCLUSIONS: These findings provide evidence that in failing human myocardium caused by dilated cardiomyopathy, protein levels of SERCA II and phospholamban are unchanged even though mRNA levels for SERCA II and phospholamban and the SERCA II function are reduced compared with nonfailing myocardium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586307     DOI: 10.1161/01.cir.92.11.3220

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  83 in total

1.  Intracellular calcium and the relationship to contractility in an avian model of heart failure.

Authors:  C S Kim; A J Davidoff; T M Maki; A A Doye; J K Gwathmey
Journal:  J Comp Physiol B       Date:  2000-06       Impact factor: 2.200

2.  Sarcoplasmic reticulum Ca2+ regulatory protein gene expression in human right atrium under hemodynamic overload.

Authors:  K Sadamatsu; Y Urabe; H Tsutsui; H Tagawa; F Maruoka; K Igarashi-Saito; K Takeda; Y Kawachi; H Yasui; A Takeshita
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

Review 3.  Targeting calcium cycling proteins in heart failure through gene transfer.

Authors:  Federica del Monte; Roger J Hajjar
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

Review 4.  Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure.

Authors:  Jerome Roncalli; Jörn Tongers; Douglas W Losordo
Journal:  Arch Cardiovasc Dis       Date:  2010-06-23       Impact factor: 2.340

5.  Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy. Functional evidence for alterations in intracellular Ca2+ handling.

Authors:  B Pieske; M Sütterlin; S Schmidt-Schweda; K Minami; M Meyer; M Olschewski; C Holubarsch; H Just; G Hasenfuss
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

6.  Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice.

Authors:  M C Colbert; D G Hall; T R Kimball; S A Witt; J N Lorenz; M L Kirby; T E Hewett; R Klevitsky; J Robbins
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 7.  [Reverse remodeling of the intracellular Ca(2+)-homeostasis: new concepts of pathophysiology and therapy of heart failure].

Authors:  Klara Brixius; Konrad F Frank; Birgit Bölck; Felix Hoyer; Robert H G Schwinger
Journal:  Wien Med Wochenschr       Date:  2006-04

8.  Posttranslational modifications of calcium/calmodulin-dependent protein kinase IIδ and its downstream signaling in human failing hearts.

Authors:  Tomas Rajtik; Eva Goncalvesova; Zoltan V Varga; Przemyslaw Leszek; Mariusz Kusmierczyk; Michal Hulman; Jan Kyselovic; Peter Ferdinandy; Adriana Adameova
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 9.  Protein Kinase A as a Promising Target for Heart Failure Drug Development.

Authors:  Nancy S Saad; Mohammad T Elnakish; Amany A E Ahmed; Paul M L Janssen
Journal:  Arch Med Res       Date:  2019-01-11       Impact factor: 2.235

Review 10.  Genetically changed mice with chronic deficiency or overexpression of the beta-adrenoceptors--what can we learn for the therapy of heart failure?

Authors:  Samuel Lee; Robert H G Schwinger; Klara Brixius
Journal:  Pflugers Arch       Date:  2007-09-14       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.